Valuation: DMS

Market Cap 2.27Cr 2.54Cr 2.11Cr 1.92Cr 3.61Cr 245.96Cr 3.65Cr 25Cr 9.91Cr 125.2Cr 9.53Cr 9.33Cr 401.09Cr P/E 2026 *
29.2x
P/E 2027 * 8.76x
Enterprise Value 3.81Cr 4.27Cr 3.55Cr 3.22Cr 6.07Cr 413.14Cr 6.13Cr 43Cr 17Cr 210.3Cr 16Cr 16Cr 673.72Cr EV / Sales 2026 *
0.67x
EV / Sales 2027 * 0.47x
Free-Float
69.9%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 18/07/2022
Director of Finance/CFO - 01/01/2022
Chief Tech/Sci/R&D Officer - 01/01/2019
Director TitleAgeSince
Chairman 53 18/07/2022
Director/Board Member 52 16/06/2025
Director/Board Member - 24/07/2023
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 2.56Cr
-1.52%-3.42%+20.92%+30.78% 24TCr
-0.47%-1.85%+4.16%+0.11% 15TCr
+0.21%+2.16%-5.79%+40.49% 15TCr
+1.11%-3.69%-56.16%-19.34% 6.03TCr
-1.80%-2.41%+9.80%+14.30% 4.94TCr
-0.54%-2.40%+21.37%+52.00% 4.77TCr
-0.78%+0.76%-21.16%-19.35% 4.8TCr
+0.83%-0.21%-6.98%+35.90% 4.57TCr
-1.57%-2.34%+34.80%+60.48% 4.28TCr
Average -0.52%-1.73%+0.11%+21.71% 9.32TCr
Weighted average by Cap. -0.75%-2.10%+3.80%+22.42%

Financials

2026 *2027 *
Net sales 5.68Cr 6.37Cr 5.29Cr 4.81Cr 9.06Cr 616.62Cr 9.15Cr 63Cr 25Cr 313.88Cr 24Cr 23Cr 1.01TCr 6.59Cr 7.39Cr 6.14Cr 5.58Cr 11Cr 715.42Cr 11Cr 74Cr 29Cr 364.17Cr 28Cr 27Cr 1.17TCr
Net income 8L 9L 7L 7L 12.76L 8.68Cr 12.89L 89.43L 35.01L 4.42Cr 33.66L 32.94L 14Cr 26L 29.16L 24.24L 22.03L 41.47L 28Cr 41.89L 2.91Cr 1.14Cr 14Cr 1.09Cr 1.07Cr 46Cr
Net Debt 1.54Cr 1.73Cr 1.44Cr 1.3Cr 2.46Cr 167.18Cr 2.48Cr 17Cr 6.74Cr 85Cr 6.48Cr 6.34Cr 272.63Cr 80L 89.71L 74.58L 67.79L 1.28Cr 87Cr 1.29Cr 8.94Cr 3.5Cr 44Cr 3.37Cr 3.29Cr 141.63Cr
Logo DMS
Diagnostic Medical Systems (DMS) is France's leader in the development, design, and production of imaging systems for digital and conventional radiology and osteodensitometry. The group's activity is organized around two sectors: - radiology equipment and osteodensitometers sales: mobile radiology units, floating table tops, operating room mobile amplifiers, ultrasound osteodensitometers (designed to chart the bone micro-architecture) and X ray osteodensitometers (designed to measure bone density), etc. The group also proposes devices distribution and maintenance activities; - development of biotechnology solutions: in the fields of arthrosis treatment and regenerative medicine. Products and services are marketed primarily by exclusive retailers. Net sales (not including sold divisions) are distributed geographically as follows: Europe (49.6%), North and South America (17%), Asia (7.5%), Middle East (7.5%), Africa (3.1%), Oceania (1%) and other (14.3%).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - DMS